Lucid Diagnostics (LUCD) CEO receives 2.17M-share restricted stock grant

Rhea-AI Filing Summary

Lucid Diagnostics Inc. reported that Chief Executive Officer Aklog Lishan acquired 2,170,000 shares of common stock through a restricted stock grant under the company’s 2018 Equity Plan. The grant has a single vesting date of May 20, 2029 and is subject to forfeiture if the required service period is not completed.

Following this award, Lishan directly holds 3,636,627 shares of common stock. The transaction was recorded at a price of $0.00 per share, reflecting that it is an equity compensation grant rather than an open-market purchase.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aklog Lishan

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	2,170,000	$0.00	--

Holdings After Transaction: Common Stock — 3,636,627 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aklog Lishan

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/20/2026		A		2,170,000(1)	A	$0	3,636,627	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Lucid Diagnostics (LUCD) CEO Aklog Lishan report on this Form 4?

Aklog Lishan reported receiving a grant of 2,170,000 shares of Lucid Diagnostics common stock as restricted stock under the company’s 2018 Equity Plan. This is an equity compensation award, not an open-market share purchase or sale.

How many Lucid Diagnostics (LUCD) shares did the CEO hold after the reported grant?

After the restricted stock grant, CEO Aklog Lishan held a total of 3,636,627 shares of Lucid Diagnostics common stock directly. This figure includes the newly granted restricted shares reported in the Form 4 filing.

What are the vesting terms of the Lucid Diagnostics (LUCD) restricted stock grant?

The 2,170,000 restricted shares granted to CEO Aklog Lishan vest on a single date of May 20, 2029. The shares are subject to forfeiture if he does not complete the requisite service period through that vesting date.

Was there a purchase price for the Lucid Diagnostics (LUCD) CEO’s restricted stock grant?

The restricted stock grant to CEO Aklog Lishan was reported at a price of $0.00 per share. This indicates a compensatory equity award rather than a cash-funded, open-market stock purchase transaction.

Under which plan were the Lucid Diagnostics (LUCD) restricted shares granted to the CEO?

The 2,170,000 restricted shares reported for CEO Aklog Lishan were granted under Lucid Diagnostics’ 2018 Equity Plan. This plan is used by the company to provide stock-based compensation awards to eligible participants.